Cancer clinical trials in the region Auvergne-Rhône-Alpes

498 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes
Phase 2 Colon cancer Rectal cancer Anal cancer #NCT04268121 #2024-515603-19-01
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
10 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 Breast cancer #NCT05973864 #2023-505291-30-01
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery Immunotherapy Chemotherapy
20 recruiting sites
UNICANCER
Phase 2 Lung cancer #NCT06667076 #2025-520730-28-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None 1
4 recruiting sites
Janssen
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Stomach and esophageal cancer Sarcoma and GIST #NCT05152472 #2022-503068-34-00
Required histologic types
GIST
Required histologic sub types
Gastrointestinal stromal tumor
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
11 recruiting sites
Centre Léon Bérard
Phase 2 Liver and bile duct cancer #NCT06254248 #2024-514400-14-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Transplant
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 2 Penile cancer and germ cell tumors #NCT05529251 #2024-514636-25-00
Required histologic types
Germ cell tumor
Required histologic sub types
Pure seminoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required primary sites
Testis
Required IGCCCG prognostic scores
Good prognosis
Excluded previous treatments at localized stage
Surgery Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
11 recruiting sites
Centre Léon Bérard
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05128825
Partie partie 2b et 2c (Cyclin E1 positive)
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05183984 #2023-504166-37-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required FIGO stages
Stage III
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
7 recruiting sites
Groupe ARCAGY/GINÉCO
Phase 2 Stomach and esophageal cancer Sarcoma and GIST #NCT05009927 #2024-512631-77-00
Required histologic types
GIST
Required histologic sub types
Gastrointestinal stromal tumor
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KIT
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Centre Léon Bérard